Ravi Salgia, MD, PhD
It is an exciting time in the treatment landscape of ALK
-positive non–small cell lung cancer (NSCLC), as there have been a number of regulatory decisions and clinical trial findings with regard to ALK-specific tyrosine kinase inhibitors (TKIs), explains Ravi Salgia, MD, PhD.
-directed therapies for patients with NSCLC.
OncLive: Can you speak to how newer ALK inhibitors are being developed to counter resistance?
Salgia: I discussed many ALK
trials in NSCLC. I was one of the physicians involved in bringing crizotinib to fruition. When we designed the clinical trial initially, that was the compound known as PF02341066. Based on that, it was supposed to be a MET inhibitor, which it is, but then we also realized with our colleagues that it was an ALK inhibitor. That is how the phase I clinical trial was done that was published in the New England Journal of Medicine
. Ultimately, it became FDA approved because there was such a strong progression-free survival (PFS)—even in third-line, fourth-line, and fifth-line therapies—with crizotinib.
... to read the full story